TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 453-472

  Sedger, Lisa M ^a,b   McDermott, Michael F ^c  

^a MACQUARIE UNIVERSITY   (Australia)

^b Australian National University   (Australia)

^c The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

Author keywords

Inflammation; Monoclonal antibody; Neuropathology; Tumor necrosis factor; Tumor necrosis factor receptor

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ADALIMUMAB; CASPASE 8; CERTOLIZUMAB PEGOL; CTP 13; CURCUMIN; ETANERCEPT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; ONERCEPT; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECOMBINANT TUMOR NECROSIS FACTOR; SPHINGOMYELIN PHOSPHODIESTERASE; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE LEUKEMIA; ALZHEIMER DISEASE; ANKYLOSING SPONDYLITIS; ANTIBACTERIAL ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; CARDIOVASCULAR DISEASE; CELL DEATH; CHILL; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMYELINATING DISEASE; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DYSPNEA; ENZYME ACTIVATION; ERYTHEMA NODOSUM LEPROSUM; FEVER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOTENSION; IATROGENIC IMMUNODEFICIENCY ASSOCIATED LYMPHOPROLIFERATIVE DISEASE; IMMUNE DEFICIENCY; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION RISK; INFLAMMATION; INFLAMMATORY DISEASE; LYMPHOPROLIFERATIVE DISEASE; MEDIATOR RELEASE; MONOTHERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NAUSEA; NERVOUS SYSTEM INFLAMMATION; NEUROBIOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TACHYCARDIA; TREATMENT RESPONSE; UBIQUITINATION; VOMITING; ANTAGONISTS AND INHIBITORS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; APOPTOSIS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFLAMMATION; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 84908015088     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.016     Document Type: Short Survey

References (358)

1. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666-3670.
2. Green S., Dobrjansky A., Chiasson M.A. Murine tumor necrosis-inducing factor: purification and effects on myelomonocytic leukemia cells. J Natl Cancer Inst 1982, 68:997-1003.
3. Matthews N., Ryley H.C., Neale M.L. Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization. Br J Cancer 1980, 42:416-422.
4. Ruff M.R., Gifford G.E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol 1980, 125:1671.
5. Matthews N. Tumour-necrosis factor from the rabbit. III. Relationship to interferons. Br J Cancer 1979, 40:534-539.
6. Prince H.E., Anderson W.L., Tomasi T.B. Inhibition of L-cell growth in agarose (ILGA): a simple inexpensive method for the detection and quantitation of factors inhibiting tumor cell growth. J Immunol Methods 1982, 48:367-372.
7. Bloksma N., Kuper C.F., Hofhuis F.M., Benaissa-Trouw B., Willers J.M. Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo. Cancer Immunol Immunother 1983, 16:35-39.
8. Williamson B.D., Carswell E.A., Rubin B.Y., Prendergast J.S., Old L.J. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A 1983, 80:5397-5401.
9. English B.K., Weaver W.M., Wilson C.B. Differential regulation of lymphotoxin and tumor necrosis factor genes in human T lymphocytes. J Biol Chem 1991, 266:7108-7113.
10. Kelker H.C., Oppenheim J.D., Stone-Wolff D., Henriksen-DeStefano D., Aggarwal B.B., Stevenson H.C., et al. Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin. Int J Cancer 1985, 36:69-73.
11. Turner M., Feldmann M. Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA. Biochem Biophys Res Commun 1988, 153(3):1144-1151.
12. Fransen L., Müller R., Marmenout A., Tavernier J., Van der Heyden J., Kawashima E., et al. Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res 1985, 13:4417-4429.
13. Shirai T., Yamaguchi H., Ito H., Todd C.W., Wallace R.B. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 1985, 313:803-806.
14. Wang A.M., Creasey A.A., Ladner M.B., Lin L.S., Strickler J., Van Arsdell J.N., et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985, 228:149-154.
15. Haranaka K., Satomi N., Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984, 34:263-267.
16. Ziegler-Heitbrock H.W., Möller A., Linke R.P., Haas J.G., Rieber E.P., Riethmüller G. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res 1986, 46:5947-5952.
17. Haranaka K., Satomi N., Sakurai A., Haranaka R. Antitumour effects of tumour necrosis factor: cytotoxic or necrotizing activity and its mechanism. Ciba Found Symp 1987, 131:140-153.
18. Creaven P.J., Plager J.E., Dupere S., Huben R.P., Takita H., Mittelman A., et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987, 20:137-144.
19. Feinberg B., Kurzrock R., Talpaz M., Blick M., Saks S., Gutterman J.U. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988, 6:1328-1334.
20. Schwartz J.E., Scuderi P., Wiggins C., Rudolph A., Hersh E.M. A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1989, 1:207-214.
21. Zamkoff K.W., Newman N.B., Rudolph A.R., Young J., Poiesz B.J. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. J Biol Response Mod 1989, 8:539-552.
22. Negrier M.S., Pourreau C.N., Palmer P.A., Ranchere J.Y., Mercatello A., Viens P., et al. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. J Immunother 1991, 11:93-102.
23. Roberts N.J., Zhou S., Diaz L.A.J., Holdhoff M. Systemic use of tumor necrosis factor-α as an anticancer agent. Oncotarget 2011, 2:739-751.
24. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985, 4716.
25. Shalaby M.R., Waage A., Aarden L., Espevik T. Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989, 53:488-498.
26. Zhang Y.H., Lin J.X., Yip Y.K., Vilcek J. Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6. Proc Natl Acad Sci U S A 1988, 85:6802-6805.
27. Falvo J.V., Tsytsykova A.V., Goldfeld A.E. Transcriptional control of the TNF gene. Curr Dir Autoimmun 2010, 11:27-60.
28. Tsai E.Y., Yie J., Thanos D., Goldfeld A.E. Cell-type-specific regulation of the human tumor necrosis factor-α gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol 1996, 16:5232-5244.
29. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Johnson J.M., Mathisen P.M., et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998, 164:93-100.
30. Stamou P., Kontoyiannis D.L. Posttranscriptional regulation of TNF mRNA: a paradigm of signal-dependent mRNA utilization and its relevance to pathology. Curr Dir Autoimmun 2010, 11:61-79.
31. Zhang T., Kruys V., Huez G., Gueydan C. AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochem Soc Trans 2002, 30:952-958.
32. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1995, 385:729-733.
33. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385:733-736.
34. Tartaglia L.A., Weber R.F., Figari I.S., Reynolds C., Palladino M.A.J., Goeddel D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A 1991, 88:9292-9296.
35. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
36. Carpentier I., Coornaert B., Beyaert R. Function and regulation of tumor necrosis factor type 2. Curr Med Chem 2004, 11:2205-2212.
37. Aggarwal B.B., Eessalu T.E., Hass P.E. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985, 318:665-667.
38. Tsujimoto M., Yip Y.K., Vilcek J. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J Immunol 1986, 136:2441-2444.
39. Tartaglia L.A., Pennica D., Goeddel D.V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993, 268:18542-18548.
40. Eissner G., Kolch W., Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004, 15:353-366.
41. Watts A.D., Hunt N.H., Wanigasekara Y., Bloomfield G., Wallach D., Roufogalis B.D., et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J 1999, 18:2119-2126.
42. Xin L., Wang J., Zhang H., Shi W., Yu M., Li Q., et al. Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNFα-mediated 'reverse signaling'. Int J Mol Med 2006, 18:885-892.
43. Zhang H., Yan D., Shi X., Liang H., Pang Y., Qin N., et al. Transmembrane TNF-alpha mediates "forward" and "reverse" signaling, inducing cell death or survival via the NF-κB pathway in Raji Burkitt lymphoma cells. J Leukoc Biol 2008, 84:789-797.
44. Higuchi M., Nagasawa K., Horiuchi T., Oike M., Ito Y., Yasukawa M., et al. Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation-characterization of membrane TNF-α. Clin Immunol Immunopathol 1997, 82:133-140.
45. Parry S.L., Sebbag M., Feldmann M., Brennan F.M. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol 1997, 158:3673-3681.
46. Xin L.W.J., Zhang H., Shi W., Yu M., Li Q., Jiang X., et al. Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated 'reverse signaling'. Int J Mol Med 2006, 18:885-892.
47. Eissner G., Kirchner S., Lindner H., Kolch W., Janosch P., Grell M., et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000, 164:6193-6198.
48. Hayder H., Blanden R.V., Körner H., Riminton D.S., Sedgwick J.D., Müllbacher A. Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF or lymphotoxin. J Immunol 1999, 163:1516-1520.
49. Ruddle N.H. Lymphotoxin and TNF: how it all began-A tribute to the travelers. Cytokine Growth Factor Rev 2014, 25:83-89.
50. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
51. Tartaglia L.A., Rothe M., Hu Y.F., Goeddel D.V. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 1993, 73:213-216.
52. Jiang Y., Woronicz J.D., Liu W., Goeddel D.V. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999, 283:543-546.
53. Takada H., Chen N.J., Mirtsos C., Suzuki S., Suzuki N., Wakeham A., et al. Role of SODD in regulation of tumor necrosis factor responses. Mol Cell Biol 2003, 23:4026-4033.
54. Hsu H., shu H.-B., Pan M.-G., Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84:299-308.
55. Hsu H., Xiong J., Goeddel D.V. The TNF receptor-1 associated protein TRADD signals cell death and NF-κB activation. Cell 1995, 81:495-504.
56. Rothe M., Sarma V., Dixit V.M., Goeddel D.V. TRAF2 mediated activation of NF-κB by TNF receptor-2 and CD40. Science 1995, 269:1424-1427.
57. Rothe M., Wong S.C., Henzel M.J., Goeddel D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75kDa tumour necrosis factor receptor. Cell 1994, 78:681-692.
58. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
59. Ho P.K., Hawkins C.J. Mammalian initiator apoptotic caspases. FEBS J 2005, 272:5436-5453.
60. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391:43-50.
61. Muzio M., Cunniaiyan A.M., Kischkel F.C., O'Rouke K., Schevchenko A., Ni J., et al. Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signalling complex. Cell 1996, 85:817-827.
62. Vince J.E., Pantaki D., Feltham R., Mace P.D., Cordier S.M., Schmukle A.C., et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (TNF) to efficiently activate NF-κB and to prevent TNF-induced apoptosis. J Biol Chem 2009, 284:35906-35915.
63. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S.J. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
64. Darzynkiewicz Z., Williamson B., Carswell E.A., Old L.J. Cell cycle-specific effects of tumor necrosis factor. Cancer Res 1984, 44:83-90.
65. Austgulen R., Espevik T., Hammerstrøm J., Nissen-Meyer J. Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells. Cancer Res 1986, 46:4566-4570.
66. Munker R., Koeffler P. In vitro action of tumor necrosis factor on myeloid leukemia cells. Blood 1987, 69:1102-1108.
67. Suyama K., Goldstein J., Green S. Effects of murine tumor necrosis factor on friend erythroleukemic cells. Exp Cell Biol 1985, 53:85-92.
68. Sedger L.M., Shows D.M., Blanton R.A., Peschon J.J., Goodwin R.G., Cosman D., et al. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999, 163:920-926.
69. Wong G.H., Tartaglia L.A., Lee M.S., Goeddell D.V. Antiviral activity of tumour necrosis factor is signaled through the 55-kDa type I TNF receptor. J Immunol 1992, 149:3350-3353.
70. Mak T.W., Yeh W.C. Signaling for survival and apoptosis in the immune system. Arthritis Res 2002, 4:S243-S252.
71. Natoli G., Costanzo A., Ianni A., Templeton D.J., Woodgett J.R., Balsano C., et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 1997, 275:200-203.
72. Song H.Y., Regnier C.H., Kirschning C.J., Goeddel D.V., Rothe M. Tumor necrosis factor (TNF)- mediated kinase cascades: bifurcation of nuclear factor-κB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A 1997, 94:9792-9796.
73. Shikama Y., Yamada M., Miyashita T. Caspase-8 and caspase-10 activate NF-κB through RIP, NIK and IKKα kinases. Eur J Immunol 2004, 33:1998-2006.
74. Zuckerman S.H., Evans G.F., Guthrie L. Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA. Immunology 1991, 73:460-465.
75. Gupta S., Campbell D., Dérijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995, 267:389-393.
76. Westwick J.K., Weitzel C., Minden A., Karin M., Brenner D.A. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J Biol Chem 1994, 269:26396-26401.
77. Kohase M., Henriksen-DeStefano D., May L.T., Vilcek J., Sehgal P.B. Induction of beta 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell 1986, 45:659-666.
78. Fransen L., Van der Heyden J., Ruysschaert R., Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986, 22:419-426.
79. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008, 9:1371-1378.
80. Liao G., Zhang M., Harhaj E.W., Sun S.C. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004, 279:26243-26250.
81. Qing G., Qu Z., Xiao G. Stabilization of basally translated NF-κB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-κB2 p100. J Biol Chem 2005, 280:40578-40582.
82. Razani B., Zarnegar B., Ytterberg A.J., Shiba T., Dempsey P.W., Ware C.F., et al. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKα-mediated phosphorylation. Sci Signal 2010, 3:ra41.
83. McPherson A.J., Snell L.M., Mak T.W., Watts T.H. Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells. J Biol Chem 2012, 287:23010-23019.
84. Michel M., Wilhelmi I., Schultz A.S., Preussner M., Heyd F. Activation-induced tumor necrosis factor receptor-associated factor 3 (Traf3) alternative splicing controls the noncanonical nuclear factor κB pathway and chemokine expression in human T cells. J Biol Chem 2014, 289:13651-13660.
85. Xie P., Kraus Z.J., Stunz L.L., Liu Y., Bishop G.A. TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling. J Immunol 2011, 186:143-155.
86. Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E., Haas T.L., et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011, 471:591-596.
87. Haas T.L., Emmerich C.H., Gerlach B., Schmukle A.C., Cordier S.M., Rieser E., et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 1999, 36:831-844.
88. Ikeda F., Deribe Y.L., Skånland S.S., Stieglitz B., Grabbe C., Franz-Wachtel M., et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 2011, 471:637-641.
89. Tokunaga F., Nakagawa T., Nakahara M., Saeki Y., Taniguchi M., Sakata S., et al. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 2011, 471:633-636.
90. Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K., et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat Cell Biol 2009, 11:123-132.
91. Chaudhary P.M., Eby M.T., Jasmin A., Kumar A., Liu L., Hood L. Activation of the NF-κB pathway by caspase 8 and its homologs. Oncogene 2000, 19:4451-4460.
92. Kataoka T., Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway. Mol Cell Biol 2004, 24:2627-2636.
93. Matsuda I., Matsuo K., Matsushita Y., Haruna Y., Niwa M., Kataoka T. The C-terminal domain of the long form of cellular FLICE-inhibitory protein (c-FLIPL) inhibits the interaction of the caspase 8 prodomain with the receptor-interacting protein 1 (RIP1) death domain and regulates caspase 8-dependent nuclear factor κB (NF-κB) activation. J Biol Chem 2014, 289:3876-3887.
94. Deng Y., Ren X., Yang L., Lin Y., Wu X. A JNK-dependent pathway is required for TNFα-induced apoptosis. Cell 2003, 115:61-70.
95. Schwabe R.F., Uchinami H., Qian T., Bennett B.L., Lemasters J.J., Brenner D.A. Differential requirement for c-Jun NH2-terminal kinase in TNFα-Fas-mediated apoptosis in hepatocytes. FASEB J 2004, 18:720-722.
96. Ruby J., Bluethmann H., Peschon J.J. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med 1997, 186:1591-1596.
97. Sedger L.M. Viral inhibition of tumour necrosis factor-α and TNFα and TNF-receptor induced apoptosis and inflammation. Curr Med Chem Anti Inflam Anti Aller 2005, 4:597-615.
98. Hiscott J., Nguyen T.L., Arguello M., Nakhaei P., Paz S. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 2006, 25:6844-6867.
99. Mohamed M.R., McFadden G. NFκB inhibitors: strategies from poxviruses. Cell Cycle 2009, 8:3125-3132.
100. Komiyama T., Ray C.A., Pickup D.J., Howard A.D., Thornberry N.A., Peterson E.P., et al. Inhibition of interleukin-1 beta converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition. J Biol Chem 1994, 269:19331-19337.
101. Tewari M., Dixit V.M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 1995, 270:3255-3260.
102. Thome M., Schneider P., Hoffman K., Fickenscher H., Meinl E., Neipel F., et al. Viral FLICE-inhibitory proteins (FLIPS) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
103. Chan F.K., Shisler J., Bixby J.G., Felices M., Zheng L., Appel M., et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem 2003, 278:51613-51621.
104. Warzocha K., Bienvenu J., Coiffier B., Salles G. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokine Netw 1995, 6:83-96.
105. Schütze S., Machleidt T., Krönke M. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 1994, 56:533-541.
106. Schütze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K., Krönke M. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992, 71:765-776.
107. Fiers W., Brouckaert P., Goldberg A.L., Kettelhut I., Suffys P., Tavernier J., et al. Structure-function relationship of tumour necrosis factor and its mechanism of action. Ciba Found Symp 1987, 131:109-123.
108. Adam-Klages S., Adam D., Wiegmann K., Struve S., Kolanus W., Schneider-Mergener J., et al. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 1996, 86:937-947.
109. Heinrich M., Neumeyer J., Jakob M., Hallas C., Tchikov V., Winoto-Morbach S., et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ 2004, 11:550-563.
110. Heinrich M., Wickel M., Winoto-Morbach S., Schneider-Brachert W., Weber T., Brunner J., et al. Ceramide as an activator lipid of cathepsin D. Adv Exp Med Biol 2000, 477:305-315.
111. Peppelenbosch M., Boone E., Jones G.E., van Deventer S.J., Haegeman G., Fiers W., et al. Multiple signal transduction pathways regulate TNF-induced actin reorganization in macrophages: inhibition of Cdc42-mediated filopodium formation by TNF. J Immunol 1991, 162:837-845.
112. Boecke A., Sieger D., Neacsu C.D., Kashkar H., Krönke M. Factor associated with neutral sphingomyelinase activity mediates navigational capacity of leukocytes responding to wounds and infection: live imaging studies in zebrafish larvae. J Immunol 2012, 189:1559-1566.
113. Nixon G.F. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 2009, 158:982-993.
114. Takeda K., Iwamoto S., Sugimoto H., Takuma T., Kawatani N., Noda M., et al. Identity of differentiation inducing factor and tumour necrosis factor. Nature 1987, 323:338-340.
115. Trinchieri G., Kobayashi M., Rosen M., Loudon R., Murphy M., Perussia B. Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med 1986, 164:1206-1225.
116. Jelinek D.F., Lipsky P.E. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-α and interleukin 1. J Immunol 1987, 139:2970-2976.
117. Kehrl J.H., Miller A., Fauci A.S. Effect of tumor necrosis factor-α on mitogen-activated human B cells. J Exp Med 1987, 166:786-791.
118. Palombella V.J., Mendelsohn J., Vilcek J. Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor. J Cell Physiol 1988, 135:23-31.
119. Vilcek J., Palombella V.J., Henriksen-DeStefano D., Swenson C., Feinman R., Hirai M., et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986, 163:632-643.
120. Dinarello C.A., Cannon J., Wolff G., Bernheim S.M., Beutler H.A., Cerami B.A., et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986, 164:1443-1450.
121. Philip R., Epstein L.B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1. Nature 1986, 323:86-89.
122. Brouckaert P., Spriggs D.R., Demetri G., Kufe D.W., Fiers W. Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon-γ. J Exp Med 1989, 169:2257-2262.
123. Christoforidis D., Chassot P.G., Mosimann F., Lienard D., Brunstein F., Bejko D., et al. Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response. Arch Surg 2003, 138:17-25.
124. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989, 169:333-338.
125. Waage A., Halstensen A., Shalaby R., Brandtzaeg P., Kierulf P., Espevik T. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis, relation to the inflammatory response. J Exp Med 1989, 170:1859-1867.
126. Dinarello C.A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991, 163:1177-1184.
127. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
128. Rebelo S.L., Bainbridge S.E., Amel-Kashipaz M.R., Radford P.M., Powell R.J., Todd I., et al. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006, 54:2674-2687.
129. Todd I., Radford P.M., Draper-Morgan K.A., McIntosh R., Bainbridge S., Dickinson P., et al. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004, 113:65-79.
130. Yousaf N., Gould D.J., Aganna E., Hammond L., Mirakian R.M., Turner M.D., et al. Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation. Arthritis Rheum 2005, 52:2906-2916.
131. Lobito A.A., Kimberley F.C., Muppidi J.R., Komarow H., Jackson A.J., Hull K.M., et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006, 108:1320-1327.
132. Bulua A.C., Simon A., Maddipati R., Pelletier M., Park H., Kim K.Y., et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011, 208:519-533.
133. Dickie L.J., Aziz A.M., Savic S., Lucherini O.M., Cantarini L., Geiler J., et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 2012, 71:2035-2043.
134. Kimberley F.C., Lobito A.A., Siegel R.M., Screaton G.R. Falling into TRAPS - receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 2007, 9:217.
135. Savic S., Dickie L.J., Wittmann M., McDermott M.F. Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol 2012, 26:505-533.
136. Bulua A.C., Mogul D.B., Aksentijevich I., Singh H., He D.Y., Muenz L.R., et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012, 64:908-913.
137. Vaitla P.M., Radford P.M., Tighe P.J., Powell R.J., McDermott E.M., Todd I., et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011, 63:1151-1155.
138. Cantarini L., Lucherini O.M., Muscari I., Frediani B., Galeazzi M., Brizi M.G., et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 2012, 12:38-43.
139. Wong G.H.W., Goeddel D.V. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 1986, 323:819-822.
140. Yamaguchi Y., Tsumura H., Miwa M., Inaba K. Contrasting effects of TGFβ1 and TNFα on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 1997, 15:144-153.
141. Takashiba S., Van Dyke T.E., Amar S., Murayama Y., Soskolne A.W., Shapira L. Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor κB. Infect Immun 1999, 67:5573-5578.
142. Harris J., Hope J.C., Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis 2008, 198:1842-1850.
143. Zhou D., Huang C., Lin Z., Zhan S., Kong L., Fang C., et al. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal 2014, 26:192-197.
144. Cohen H.B., Mosser D.M. Extrinsic and intrinsic control of macrophage inflammatory responses. J Leukoc Biol 2013, 94:913-919.
145. + T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1997, 177:1575-1585.
146. Upton C., Macen J.L., Schreiber M., McFadden G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 1991, 184:370-382.
147. Schreiber M., McFadden G. The myxoma virus TNF-receptor homologue (T2) inhibits tumor necrosis factor-α in a species-specific fashion. Virology 1994, 204:692-705.
148. Schreiber M., Rajarathnam K., McFadden G. Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFα, but the dimer is a more potent TNF inhibitor. J Biol Chem 1996, 271:13333-13341.
149. Schreiber M., Sedger L., McFadden G. Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol 1997, 71:2171-2181.
150. Sedger L., McFadden G. M-T2: a poxvirus TNF receptor homologue with dual activities. Immunol Cell Biol 1996, 74:538-545.
151. Skelly D.T., Hennessy E., Dansereau M.A., Cunningham C. A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1B, TNF-α and IL-6 challenges in C57BL/6 mice. PLoS One 2013, 8:e69123.
152. Thomson C.A., McColl A., Cavanagh J., Graham G.J. Peripheral inflammation is associated with remote global gene expression changes in the brain. J Neuroinflammation 2014, 11:73.
153. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther 2010, 128:519-548.
154. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45.
155. Kogo J., Takeba Y., Kumai T., Kitaoka Y., Matsumoto N., Ueno S., et al. Involvement of TNF-α in glutamate-induced apoptosis in a differentiated neuronal cell line. Brain Res 2006, 1122:201-208.
156. Kisiswa L., Osório C., Erice C., Vizard T., Wyatt S., Davies A.M. TNFα reverse signaling promotes sympathetic axon growth and target innervation. Nat Neurosci 2013, 16:865-873.
157. Siegel S.A., Shealy D.J., Nakada M.T., Le J., Woulfe D.S., Probert L., et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995, 7:15-25.
158. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995, 7:251-259.
159. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
160. den Broeder A.A., Joosten L.A., Saxne T., Heinegård D., Fenner H., Miltenburg A.M., et al. Long term anti-tumour necrosis factor-α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002, 61:311-318.
161. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
162. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
163. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
164. Lethaby A., Lopez-Olivo M.A., Maxwell L., Burls A., Tugwell P., Wells G. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2013, 5:CD004525.
165. van der Heijde D., Klareskog L., Rodriguez-Valverde V., Codreanu C., Bolosiu H., Melo-Gomes J., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074.
166. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
167. Hutas G. Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies. Immunotherapy 2010, 2:453-460.
168. Smolen J.S., Kay J., Doyle M.K., Landewé R., Matteson E.L., Wollenhaupt J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor-α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221.
169. Oldfield V., Plosker G.L. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs 2009, 23:125-135.
170. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002, 54:531-545.
171. Bourne T., Fossati G., Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008, 22:331-337.
172. Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
173. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O.Ø., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
174. Geiler J., Buch M., McDermott M.F. Anti-TNF treatment in rheumatiod athritis. Curr Pharm Des 2011, 17:3141-3154.
175. Meroni P.-L., Valesini G. Tumour necrosis factor-α antagonists in the treatment of Rheumatoid arthritis: an immunological perspective. BioDrugs 2014, 28:S5-S13.
176. Edwards C.K.I. PEGylated recombinat human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-R1): novel high affinity TNF receptor desgined for chonic inflammatory diseases. Ann Rheum Dis 1999, 58:I73-I81.
177. Bendele A.M., McComb J., Gould T., Frazier J., Chlipala E., Seely J., et al. Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol 1999, 17:553-560.
178. McComb J., Gould T., Chlipala E., Sennelo G., Frazier J., Kieft G., et al. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol 1999, 26:1347-1351.
179. Trinchard-Lugan I., Ho-Nhuyen Q., Bilham W.M., Buralio M., Ythier A., Munafo A. Safety, pharmakinetics and pharmacodynamics of recombinant human tumour necrosis factor binding proteins-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur Cytokine Netw 2001, 12:391-398.
180. Kay J., Smolen J.S. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013, 72:1589-1593.
181. Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012, 8:430-436.
182. Yoo D.H., Hrycaj P., Miranda P., Ramiterre E., Piotrowski M., Shevchuk S., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.
183. Park W., Hrycaj P., Jeka S., Kovalenko V., Lysenko G., Miranda P., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013, 72:1605-1612.
184. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30:85-94.
185. Fürst R., Zündorf I. Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediat Inflamm 2014, 2014:146832.
186. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
187. Sharma R.A., Steward W.P., Gescher A.J. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007, 595:453-470.
188. Doggui S., Sahni J.K., Arseneault M., Dao L., Ramassamy C. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimers Dis 2012, 20:377-392.
189. Ray B., Bisht S., Maitra A., Maitra A., Lahiri D.K. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J Alzheimers Dis 2011, 23:61-77.
190. Monroy A., Lithgow G.J., Alavez S. Curcumin and neurodegenerative diseases. Biofactors 2013, 39:122-132.
191. Somers G.F. Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol Chemother 1960, 15:111-116.
192. Leck I.M., Millar E.L. Incidence of malformations since the introduction of thalidomide. Br Med J 1962, 2:16-20.
193. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002, 168:2644-2651.
194. Majumder S., Sreedhara S.R., Banerjee S., Chatterjee S. TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide. Curr Top Med Chem 2012, 12:1456-1467.
195. Zhou S., Wang F., Hsieh T.C., Wu J.M., Wu E. Thalidomide-a notorious sedative to a wonder anticancer drug. Curr Med Chem 2013, 20:4102-4108.
196. Tweedie D., Ferguson R.A., Fishman K., Frankola K.A., Van Praag H., Holloway H.W., et al. Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflamm 2012, 9:106.
197. He P., Cheng X., Staufenbiel M., Li R., Shen Y. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. PLoS One 2013, 8:e55091.
198. Kirchner S., Holler E., Haffner S., Andreesen R., Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004, 28:67-74.
199. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S., Kikuchi Y., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 2005, 128:376-392.
200. Ringheanu M., Daum F., Markowitz J., Levine J., Katz S., Lin X., et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004, 10:801-810.
201. Xin L., Wang J., Zhang H., Shi W., Yu M., Li Q., et al. Dual regulation of soluble tumour necrosis factor-α inducing activation of human monocytic cells via modulation transmembrane TNFα-metiated "reverse signalling". Int J Mol Med 2006, 18:885-892.
202. Marotte H., Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?. Expert Opin Biol Ther 2014, 14:569-572.
203. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
204. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:5.
205. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S., Kikuchi Y., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 2005, 128:376-392.
206. Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010, 10:308-315.
207. Di Sabatino A., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004, 53:70-77.
208. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
209. Vos A.C., Wildenberg M.E., Duijvestein M., Verhaar A.P., van den Brink G.R., Hommes D.W. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011, 140:221-230.
210. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323-1332.
211. Furst D.E., Wallis R., Broder M., Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006, 36:159-167.
212. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 2005, 34:12-18.
213. Feagan B.G., Sandborn W.J., Baker J.P., Cominelli F., Sutherland L.R., Elson C.O., et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005, 21:373-384.
214. Sandborn W.J., Feagan B.G., Radford-Smith G., Kovacs A., Enns R., Innes A., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485-1493.
215. + T regulatory cells. J Immunol 2007, 179:154-161.
216. Nie H., Zheng Y., Li R., Guo T.B., He D., Fang L., et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNFα in rheumatoid arthritis. Nat Med 2013, 19:322-328.
217. Singh S., Aggarwal B.B. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995, 270:24995-25000.
218. Kim G.Y., Kim K.H., Lee S.H., Yoon M.S., Lee H.J., Moon D.O., et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-κB as potential targets. J Immunol 2005, 174:8116-8124.
219. Zhong Y., Liu T., Guo Z. Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF-κB pathways in rat vascular smooth muscle cells. Inflamm Res 2012, 61:61-67.
220. Hong J., Bose M., Ju J., Ryu J.H., Chen X., Sang S., et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004, 25:1671-1679.
221. Kang G., Kong P.J., Yuh Y.J., Lim S.Y., Yim S.V., Chun W., et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor κB bindings in BV2 microglial cells. J Pharmacol Sci 2004, 94:325-328.
222. Karlstetter M., Lippe E., Walczak Y., Moehle C., Aslanidis A., Mirza M., et al. Curcumin is a potent modulator of microglial gene expression and migration. J Neuroinflamm 2011, 8:125.
223. Zhong Y., Yu W., Feng J., Fan Z., Li J. Curcumin suppresses tumor necrosis factor-α-induced matrix metalloproteinase-2 expression and activity in rat vascular smooth muscle cells via the NF-κB pathway. Exp Ther Med 2014, 7:1653-1658.
224. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
225. van Schouwenburg P.A., van de Stadt L.A., de Jong R.N., van Buren E.E., Kruithof S., de Groot E., et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013, 72:104-109.
226. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013, 108:40-47.
227. Steenholdt C., Svenson M., Bendtzen K., Thomsen O.Ø., Brynskov J., Ainsworth M.A. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis 2012, 6:108-111.
228. Garcês S., Demengeot J., Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013, 72:1947-1955.
229. van Schouwenburg P.A., Rispens T., Wolbink G.J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013, 9:164-172.
230. Ma C., Walters B., Fedorak R.N. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. World J Gastroenterol 2013, 19:3347-3351.
231. Lawrance I.C., Radford-Smith G.L., Bampton P.A., Andrews J.M., Tan P.K., Croft A., et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-α therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010, 25:1732-1738.
232. Tresch S., Trueb R.M., Kamarachev J., French L.E., Hofbauer G.F. Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept. Dermatology 2009, 219:347-349.
233. Bracaglia C., Buonuomo P.S., Tozzi A.E., Pardeo M., Nicolai R., Campana A., et al. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol 2012, 39:1287-1290.
234. Li Gobbi F., Benucci M., Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). J Clin Rheumatol 2005, 11:119-120.
235. Mancini G., Erario L., Gianfreda R., Oliva A., Massetti A.P., Mastroianni C.M., et al. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-alpha) treatment. Clin Microbiol Infect 2007, 13:1036-1037.
236. Lanternier F., Tubach F., Ravaud P., Salmon D., Dellamonica P., Bretagne S., et al. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 2013, 144:990-998.
237. Hofmann A., Beaulieu Y., Bernard F., Rico P. Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review. Can J Gastroenterol 2009, 23:829-833.
238. Kang M.J., Kim M.S., Choi E.H., Lee K.E., Kim Y.K., Choi H.J. Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis. Korean J Intern Med 2007, 22:63-66.
239. Ahmad N.M., Ahmad K.M., Younus F. Severe adenoviral pneumonia (AVP) following infliximan infusion for the treatment of Crohn's disease. J Infect Dis 2007, 54:e29-e32.
240. Smith D., Letendre S. Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med 2002, 136:174.
241. Kobie J.J., Zheng B., Bryk P., Barnes M., Ritchlin C.T., Tabechian D.A., et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 2011, 13:R209.
242. Salemi S., Picchianti-Diamanti A., Germano V., Donatelli I., Di Martino A., Facchini M., et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: safety and immunogenicity. Clin Immunol 2010, 134:113-120.
243. Cantini F., Niccoli L., Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014, 91:47-55.
244. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Bréban M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
245. Harris J., Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010, 161:1-9.
246. Navarra S.V., Tang B., Lu L., Lin H.Y., Mok C.C., Asavatanabodee P., et al. Risk of tuberculosis with anti-tumour necrosis factor-α therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis 2014, 17:3.
247. Kim S.Y., Solomon D.H. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010, 6:165-174.
248. Kelsen J., Dige A., Schwindt H., D'Amore F., Pedersen F.S., Agnholt J., et al. Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: a predictor of lymphoma risk?. PLoS One 2011, 6:e17890.
249. Tripodo C., Iannitto E., Florena A.M., Pucillo C.E., Piccaluga P.P., Franco V., et al. Gamma-delta T-cell lymphomas. Nat Rev Clin Oncol 2009, 6:707-717.
250. Wong A.K., Kerkoutian S., Said J., Rashidi H., Pullarkat S.T. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 2012, 31:631-636.
251. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
252. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 2. CD008794.
253. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998, 95:7556-7561.
254. Kuprash D.V., Qin Z., Ito D., Grivennikov S.I., Abe K., Drutskaya L.N., et al. Ablation of TNF or lymphotoxin signaling and the frequency of spontaneous tumors in p53-deficient mice. Cancer Lett 2008, 268:70-75.
255. Smyth M.J., Kelly J.M., Baxter A.G., Körner H., Sedgwick J.D. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998, 188:1611-1619.
256. Glenn W.K., Heng B., Delprado W., Iacopetta B., Whitaker N.J., Lawson J.S. Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS One 2012, 7:e48788.
257. Heng B., Glenn W.K., Ye Y., Tran B., Delprado W., Lutze-Mann L., et al. Human papilloma virus is associated with breast cancer. Br J Cancer 2009, 101:1345-1350.
258. Kan C.Y., Iacopetta B.J., Lawson J.S., Whitaker N.J. Identification of human papillomavirus DNA gene sequences in human breast cancer. Br J Cancer 2005, 93:946-948.
259. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
260. Solomon A.J., Spain R.I., Kruer M.C., Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 2011, 17:1472-1487.
261. Tanno M., Nakamura I., Kobayashi S., Kurihara K., Ito K. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 2006, 25:929-933.
262. Fromont A., De Seze J., Fleury M.C., Maillefert J.F., Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
263. Magnano M.D., Robinson W.H., Genovese M.C. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004, 22:S134-S140.
264. Andreadou E., Kemanetzoglou E., Brokalaki C., Evangelopoulos M.E., Kilidireas C., Rombos A., et al. Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med 2013, 2013:671935.
265. Kaltsonoudis E., Zikou A.K., Voulgari P.V., Konitsiotis S., Argyropoulou M.I., Drosos A.A. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 2014, 16:R125.
266. Kaltsonoudis E., Voulgari P.V., Konitsiotis S., Drosos A.A. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 2014, 13:54-58.
267. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003, 107:3133-3140. anti-TNF Therapy Against Congestive Heart Investigators.
268. Kwon H.J., Coté T.R., Cuffe M.S., Kramer J.M., Braun M.M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138:807-811.
269. Ding T., Ledingham J., Luqmani R., Westlake S., Hyrich K., Lunt M., et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010, 49:2217-2219.
270. Ledingham J., Wilkinson C., Deighton C. British thoracic society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatology (Oxford) 2005, 44:1205-1206.
271. van Breukelen-van der Stoep D.F., Klop B., van Zeben D., Hazes J.M., Castro Cabezas M. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?. Atherosclerosis 2013, 231:163-172.
272. Sugamura K., Keaney J.F.J. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2013, 51:978-992.
273. Listing J., Strangfeld A., Kekow J., Schneider M., Kapelle A., Wassenberg S., et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008, 58:667-677.
274. Barbhaiya M., Solomon D.H. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 2013, 25:317-324.
275. van Zeben D., Hazes J.M., Zwinderman A.H., Vandenbroucke J.P., Breedveld F.C. Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol 1993, 20:1288-1296.
276. Sokolove J., Zhao X., Chandra P.E., Robinson W.H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum 2011, 63:53-62.
277. Emery P., Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011, 70:2063-2070.
278. Dejaco C., Duftner C., Klotz W., Schirmer M., Herold M. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-α treatment response in rheumatoid arthritis. Rheumatol Int 2010, 30:451-454.
279. Lv Q., Yin Y., Li X., Shan G., Wu X., Liang D., et al. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS One 2014, 9:e89422.
280. Hueber W., Tomooka B.H., Batliwalla F., Li W., Monach P.A., Tibshirani R.J., et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R76.
281. Coulthard L.R., Geiler J., Mathews R.J., Church L.D., Dickie L.J., Cooper D.L., et al. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clin Exp Immunol 2013, 170:36-46.
282. Lucherini O.M., Obici L., Ferracin M., Fulci V., McDermott M.F., Merlini G., et al. First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One 2013, 8:e73443.
283. Sandborn W.J. A special meeting review edition: clinical research highlights in ibd: diagnosis and anti-tumor necrosis factor monitoring. Gastroenterol Hepatol 2013, 9(8):1-16.
284. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674-684.
285. Molnár T., Farkas K., Nyári T., Szepes Z., Nagy F., Wittmann T. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience. J Gastrointestin Liver Dis 2012, 21:265-269.
286. Baert F., Glorieus E., Reenaers C., D'Haens G., Peeters H., Franchimont D., et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2013, 7:154-160.
287. Atreya R., Neumann H., Neufert C., Waldner M.J., Billmeier U., Zopf Y., et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014, 20:313-318.
288. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997, 94:3195-3199.
289. Plant D., Bowes J., Potter C., Hyrich K.L., Morgan A.W., Wilson A.G., et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011, 63:645-653.
290. Márquez A., Ferreiro-Iglesias A., Dávila-Fajardo C.L., Montes A., Pascual-Salcedo D., Perez-Pampin E., et al. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Res Ther 2014, 16(March (2)):R66.
291. Krintel S.B., Palermo G., Johansen J.S., Germer S., Essioux L., Benayed R., et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012, 22:577-589.
292. Sode J., Vogel U., Bank S., Andersen P.S., Thomsen M.K., Hetland M.L., et al. Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome. PLoS One 2014, 9:e100361.
293. Umiċeviċ Mirkov M., Cui J., Vermeulen S.H., Stahl E.A., Toonen E.J., Makkinje R.R., et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 72:1375-1381.
294. Thomas D., Gazouli M., Karantanos T., Rigoglou S., Karamanolis G., Bramis K., et al. Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease. World J Gastroenterol 2014, 20:3609-3614.
295. Scardapane A., Breda L., Lucantoni M., Chiarelli F. TNF-α polymorphisms in juvenile idiopathic arthritis: which potential clinical implications?. Int J Rheumatol 2012, 2012:756291.
296. Mathews R.J., Robinson J.I., Battellino M., Wong C., Taylor J.C., Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 2014, 73:1202-1210.
297. Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004, 117:561-574.
298. Pétrilli V., Dostert C., Muruve D.A., Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007, 19:615-622.
299. Schoultz I., Verma D., Halfvarsson J., Törkvist L., Fredrikson M., Sjöqvist U., et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol 2009, 104:1180-1188.
300. Coulthard L.R., Taylor J.C., Eyre S., Biologics in Rheumatoid Arthritis Genetics and Genomics, Robinson J.I., Wilson A.G., et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 2011, 70:98-103.
301. Vivar N., Van Vollenhoven R.F. Advances in the treatment of rheumatoid arthritis. F1000Prime Rep 2014, 6:31.
302. McInnes I.B., Kavanaugh A., Gottlieb A.B., Puig L., Rahman P., Ritchlin C., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382:780-789.
303. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014, 73:990-999.
304. Takasaki W., Kajino Y., Kajino K., Murali R., Greene M.I. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor. Nat Biotechnol 1997, 15:15.
305. Sedger L.M., Osvath S.R., Xu X.-M., Li G., Chan F.K.-M., Barrett J., et al. Poxviral tumour necrosis factor receptor (TNFR)-like T2 proteins contain a concerved pre-ligand association domain (PLAD) that inhibits cellular TNFR2 induced cell death. J Virol 2006, 80:9300-9309.
306. Cao J., Meng F., Gao X., Dong H., Yao W. Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination. Protein J 2011, 30:281-289.
307. Deng G.-M., Zheng L., Chan F.K.-M., Lenardo M. Amelioration of inflammatory arthritis by targetting the pre-ligand assembly domain of tumour necrosis factor receptors. Nat Med 2005, 11:1304.
308. Macen J.L., Graham K.A., Lee S.F., Schreiber M., Boshkov L.K., McFadden G. Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology 1996, 218:232-237.
309. Wang Y.L., Chou F.C., Chen S.J., Lin S.H., Chang D.M., Sytwu H.K. Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - an unrevealed role in downregulation of Th17 cells. J Autoimmun 2011, 37:160-170.
310. Carter P.H., Scherle P.A., Muckelbauer J.K., Voss M.E., Liu R.Q., Thompson L.A., et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc Natl Acad Sci U S A 2001, 98:11879-11884.
311. He M.M., Smith A.S., Oslob J.D., Flanagan W.M., Braisted A.C., Whitty A., et al. Small-molecule inhibition of TNF-alpha. Science 2005, 310:1022-1025.
312. Ma L., Gong H., Zhu H., Ji Q., Su P., Liu P., et al. A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model. J Biol Chem 2014, 289:12457-12466.
313. Zhang Y., Xu J., Levin J., Hegen M., Li G., Robertshaw H., et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 2004, 309:348-355.
314. Beck G., Bottomley G., Bradshaw D., Brewster M., Broadhurst M., Devos R., et al. (E)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalero hydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-α convertase. J Pharmacol Exp Ther 2002, 302:390-396.
315. Conway J.G., Andrews R.C., Beaudet B., Bickett D.M., Boncek V., Brodie T.A., et al. J Pharmacol Exp Ther 2001, 298:900-908.
316. Coulthard L.R., Geiler J., Mathews R.J., Church L.D., Dickie L.J., Cooper D.L., et al. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clin Exp Immunol 2012, 170:36-46.
317. Cooper D.L., Martin S.G., Robinson J.I., Mackie S.L., Charles C.J., Nam J., et al. FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS One 2012, 7:e28918.
318. Getts D.R., Terry R.L., Getts M.T., Deffrasnes C., Müller M., van Vreden C., et al. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med 2014, 6(219):ra7.
319. Frankel S.R., Baeuerle P.A. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013, 17:385-392.
320. Heiss M.M., Murawa P., Koralewski P., Kutarska E., Kolesnik O.O., Ivanchenko V.V., et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010, 127:2209-2221.
321. Teachey D.T., Rheingold S.R., Maude S.L., Zugmaier G., Barrett D.M., Seif A.E., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013, 121:5154-5157.
322. Vincent K.J., Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol J 2012, 7:1444-1450.
323. Sockolosky J.T., Tiffany M.R., Szoka F.C. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A 2012, 109:16095-16100.
324. Xiao G., Gan L.S. Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol 2013, 2013:703545.
325. Sumbria R.K., Boado R.J., Pardridge W.M. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab 2012, 32:1933-1938.
326. Zhou Q.H., Sumbria R., Hui E.K., Lu J.Z., Boado R.J., Pardridge W.M. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther 2011, 339:618-623.
327. Zaremba J., Skrobanski P., Losy J. Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed Pharmacother 2001, 55:258-263.
328. Pandya J.D., Sullivan P.G., Pettigrew L.C. Focal cerebral ischemia and mitochondrial dysfunction in the TNFα-transgenic rat. Brain Res 2011, 1384:151-160.
329. Pettigrew L.C., Kindy M.S., Scheff S., Springer J.E., Kryscio R.J., Li Y., et al. Focal cerebral ischemia in the TNFα-transgenic rat. J Neuroinflamm 2008, 5:47.
330. Sumbria R.K., Zhou Q.H., Hui E.K., Lu J.Z., Boado R.J., Pardridge W.M. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol Pharm 2013, 10:1425-1431.
331. Zou L.L., Ma J.L., Wang T., Yang T.B., Liu C.B. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Curr. Neuropharmacol. 2013, 11:197-208.
332. Tobinick E. Perispinal etanercept: a new theraeutic paradigm in neurology. Expert Rev Neurother 2010, 10:985-1002.
333. Hess A., Axmann R., Rech J., Finzel S., Heindl C., Kreitz S., et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A 2011, 108:3731-3736.
334. Serratrice J., de Roux-Serratrice C., Disdier P., Dodé C., Weiller P.J. Dramatic etanercept-induced remission of relapsing febrile sciatic neuralgia related to p46l mutation of the tnfrsf1a gene. Clin Rheumatol 2007, 26:1535-1536.
335. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother 2010, 10:985-1002.
336. Taylor P., Manger B., Alvaro-Gracia J., Johnstone R., Gomez-Reino J., Eberhardt E., et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res 2010, 38:1213-1224.
337. Andrade P., Visser-Vandewalle V., Del Rosario J.S., Daemen M.A., Buurman W.A., Steinbusch H.W., et al. The thalidomide analgesic effect is associated with differential TNF-α receptor expression in the dorsal horn of the spinal cord as studied in a rat model of neuropathic pain. Brain Res 2012, 1450:24-32.
338. Li Y., Zhang Y., Liu D.B., Liu H.Y., Hou W.G., Dong Y.S. Curcumin attenuates diabetic neuropathic pain by downregulating TNFα in a rat model. Int J Med Sci 2013, 10:377-381.
339. Zhu X., Li Q., Chang R., Yang D., Song Z., Guo Q., et al. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model. PLoS One 2014, 9:e91303.
340. George A., Marziniak M., Schäfers M., Toyka K.V., Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000, 88:267-275.
341. Raedler T.J. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011, 6:519-525.
342. Simen B.B., Duman C.H., Simen A.A., Duman R.S. TNFα signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006, 59:775-785.
343. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacology 2012, 62:419-426.
344. Himmerich H., Binder E.B., Künzel H.E., Schuld A., Lucae S., Uhr M., et al. Successful antidepressant therapy restores the disturbed interplay between TNF-α system and HPA axis. Biol Psychiatry 2006, 60:882-888.
345. Montgomery S.L., Mastrangelo M.A., Habib D., Narrow W.C., Knowlden S.A., Wright T.W., et al. Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNFα suppressive therapeutic strategies in the brain. Am J Pathol 2011, 179:2053-2070.
346. Schabert V.F., Watson C., Joseph G.J., Iversen P., Burudpakdee C., Harrison D.J. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013, 19:621-630.
347. Grover A., Citro B., Mankad M., Lander F. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health. J Law Med Ethics 2012, 40:234-250.
348. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:578-582.
349. Deighton C., Hyrich K., Ding T., Ledingham J., Lunt M., Luqmani R., et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) 2010, 49:1197-1199.
350. Scott D.L., Steer S. NICE guidelines on anti-tumor necrosis factor therapy for RA. Nat Clin Pract Rheumatol 2009, 5:16-17.
351. Feagan B.G., Sandborn W.J., Lichtenstein G., Radford-Smith G., Patel J., Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 23:617-628.
352. Mamula P., Cohen S.A., Ferry G.D., Kirschner B.S., Winter H.S., Innes A., et al. CDP571, a humanized anti-tumor necrosis factor-α monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 2004, 10:723-730.
353. Glatt S., Fuseau E., Buraglio M., Nguyen Q.T. Population pharmacokinetics of onercept in healthy subjects. Clin Pharmacokinet 2005, 44:1295-1304.
354. Nikas S.N., Drosos A.A. Onercept. Serono. Curr Opin Investig Drugs 2003, 4:1369-1376.
355. Rutgeerts P., Lemmens L., Van Assche G., Noman M., Borghini-Fuhrer I., Goedkoop R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17:185-192.
356. Trinchard-Lugan I., Ho-Nguyen Q., Bilham W.M., Buraglio M., Ythier A., Munafo A. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur Cytokine Netw 2001, 12:391-398.
357. Davis M.W., Feige U., Bendele A.M., Martin S.W., Edwards C. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis 2000, 59:41-43.
358. Moreland L.W., McCabe D.P., Caldwell J.R., Sack M., Weisman M., Henry G., et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol 2000, 27:601-609.